Cristina Bulai Livideanu

Dr. Cristina Bulai Livideanu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2011 in Nature
Verified
Journal Article
Closed access
PDF file
CBCorine Bertolotto
Corine Bertolotto
FLFabienne Lesueur
Fabienne Lesueur
SGSandy Giuliano
Sandy Giuliano
TSThomas Strub
Thomas Strub
MLMahaut de Lichy
Mahaut de Lichy
BPBrigitte Bressac-de Paillerets
Brigitte Bressac-de Paillerets

1 February 2017 in The Lancet
Verified
Journal Article
Open access
OLOlivier Lortholary
Olivier Lortholary
MCMarie Olivia Chandesris
Marie Olivia Chandesris
CLCristina Bulai Livideanu
Cristina Bulai Livideanu
CPCarle Paul
Carle Paul
GGGérard Guillet
Gérard Guillet
OHOlivier Hermine
Olivier Hermine
Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18–75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries. We excluded patients with cutaneous or non-severe systemic mastocytosis after a protocol amendment. Patients were centrally randomised (1:1) to receive either oral masitinib (6 mg/kg per day over 24 weeks with possible extension) or matched placebo with minimisation according to severe symptoms. The primary endpoint was cumulative response (≥75% improvement from baseline within weeks 8–24) in at least one severe baseline symptom from the following: pruritus score of 9 or more, eight or more flushes per week, Hamilton Rating Scale for Depression of 19 or more, or Fatigue Impact Scale of 75 or more. We assessed treatment effiect using repeated measures methodology for rare diseases via the generalised estimating equation model in a modified intention-to-treat population, including all participants assigned to treatment minus those who withdrew due to a non-treatment-related cause. We assessed safety in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT00814073. Between Feb 19, 2009, and July 15, 2015, 135 patients were randomly assigned to masitinib (n=71) or placebo (n=64). By 24 weeks, masitinib was associated with a cumulative response of 18·7% in the primary endpoint (122·6 responses of 656·5 possible responses [weighted generalised estimating equation]) compared with 7·4% for placebo (48·9 of 656·5; diffierence 11·3%; odds ratio 3·6; 95% CI 1·2–10·8; p=0·0076). Frequent severe adverse events (>4% diffierence from placebo) were diarrhoea (eight [11%] of 70 in the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]). The most frequent serious adverse events were diarrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening toxicities occurred. One patient in the placebo group died (unrelated to study treatment). These study findings indicate that masitinib is an effiective and well tolerated agent for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis. AB Science (Paris, France).

6 December 2012 in Blood
Verified
Journal Article
Closed access
PDF file
ESErinn Soucie
Erinn Soucie
KHKatia Hanssens
Katia Hanssens
TMThomas Mercher
Thomas Mercher
SGSophie Georgin-Lavialle
Sophie Georgin-Lavialle
GDGandhi Damaj
Gandhi Damaj
PDPatrice Dubreuil
Patrice Dubreuil
Although a role for oncogenic KIT in driving mast cell disease is clear, the mechanisms driving the multiple phenotypic and clinical manifestations of this disorder are not well elucidated. We now show, using a large cohort of mastocytosis patients, including an almost equal number of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease. By infecting primary murine bone marrow–derived mast cells with KITD816V, we also observe a significant and competitive growth advantage for KITD816V in Tet2-nullizygous compared with wild-type cells. TET2-deficient cells display increased proliferation and can survive in the absence of cytokines. Taken together, these data demonstrate a oncogenic cooperation in mast cells and reveal TET2 mutation as a potential marker to diagnose and predict severe forms of mastocytosis.

26 January 2016 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
SGS Georgin-Lavialle
S Georgin-Lavialle
DMD S Moura
D S Moura
ASA Salvador
A Salvador
JCJ-C Chauvet-Gelinier
J-C Chauvet-Gelinier
JLJ-M Launay
J-M Launay
RGR Gaillard
R Gaillard

1 January 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
VHVivien Hébert
Vivien Hébert
CBClaire Boulard
Claire Boulard
EHEstelle Houivet
Estelle Houivet
SLSophie Duvert Lehembre
Sophie Duvert Lehembre
LBLuca Borradori
Luca Borradori
PJPascal Joly
Pascal Joly

21 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GDGandhi Damaj
Gandhi Damaj
MJMagalie Joris
Magalie Joris
OCOlivia Chandesris
Olivia Chandesris
KHKatia Hanssens
Katia Hanssens
ESErinn Soucie
Erinn Soucie
OHOlivier Hermine
Olivier Hermine
Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) is a rare and heterogeneous subtype of SM and few studies on this specific entity have been reported. Sixty two patients with Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) were presented. Myeloid AHNMD was the most frequent (82%) cases. This subset of patients were older, had more cutaneous lesions, splenomegaly, liver enlargement, ascites; lower bone mineral density and hemoglobin levels and higher tryptase level than lymphoid AHNMD. Defects in KIT, TET2, ASXL1 and CBL were positive in 87%, 27%, 14%, and 11% of cases respectively. The overall survival of patients with SM-AHNMD was 85.2 months. Within the myeloid group, SM-MPN fared better than SM-MDS or SM-AML (p = 0.044,). In univariate analysis, the presence of C-findings, the AHNMD subtypes (SM-MDS/CMML/AML versus SM-MPN/hypereosinophilia) (p = 0.044), Neutropenia (p = 0.015), high monocyte level (p = 0.015) and the presence of ASXL1 mutation had detrimental effects on OS (p = 0.007). In multivariate analysis and penalized Cox model, only the presence of ASXL1 mutation remained an independent prognostic factor that negatively affected OS (p = 0.035). SM-AHNMD is heterogeneous with variable prognosis according to the type of the AHNMD. ASXL1 is mutated in a subset of myeloid AHNMD and adversely impact on OS.